Volume :

3

Issue :

4

Abstract :

OBJECTIVES: Our objectives are to determine the safety, efficacy, rationale use of Atorvastatin in patients in a tertiary care teaching hospital and to provide information to health care providers and patients. METHODOLOGY: It was a prospective observational study which was undertaken in medicine, ICU and casualty departments of 300 bedded multi- speciality tertiary care teaching hospital, SVS hospital, for a period of 6 months. A total of 210 prescriptions were included in the study and were followed for the drug use evaluation to study. This study criterion was the in-patients and out-patients of age greater than 18yrs of either gender who are prescribed with HMG-CoA reductase inhibitor Atorvastatin. RESULTS: The drug was found to be more safe in males (97.24%) compared to females (93.85%). The drug was found to be more effective in females (98.46%) compared to males (96.55%).The drug was found to be rationally prescribed more in males (95.86%) compared to females (92.31%). In the lipid profile study, all the different parameters like serum cholesterol, High density lipoproteins (HDL), Low density lipoproteins (LDL), Very Low density lipoproteins (VLDL) and triglycerides were found to be in the normal range in about 60-70% of males, where as lipid profile parameters of females were found to be in the normal range in about 20-30% females. CONCLUSION: We conclude that the drug use was found to be safe, effective and it was rationally prescribed. Interventions for promoting more appropriate use of Atorvastatin should be implemented. Further studies from time to time are required in drug utilization pattern and standard treatment guidelines to be circulated among practicing physicians.